Latest Asx News

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

African Gold Limited has reported significant step-out drilling results at its Blaffo Guetto deposit in Côte d’Ivoire, extending gold mineralisation beyond previous estimates and reinforcing the project’s scale and potential under new Montage Gold ownership.

Redcastle Resources has reported further high-grade and broad gold intercepts from its ongoing drilling at Redcastle Reef, reinforcing confidence in the deposit's geological continuity and supporting near-term mine planning.

Regis Healthcare announces the resignation of CEO Dr Linda Mellors after six years, with a transition period underway as the board searches for her successor.

Comet Ridge Limited has obtained federal environmental approval for its Mahalo North natural gas project, paving the way for expanded development in Queensland’s Bowen Basin. This milestone complements recent ownership consolidation and state approvals, positioning the company to boost east coast gas supply.

Waypoint REIT has secured a decade-long lease extension with Viva Energy Australia on 21 sites, boosting rental income by over 12% from August 2026. The REIT also strengthens its financial footing through key refinancing moves.

Western Mines Group reports significant nickel sulphide mineralisation from deep diamond drilling at its Mulga Tank project, reinforcing its vision of a large-scale hybrid nickel system. Drilling will resume in January 2026 to extend these promising results.

Cann Group Limited has launched a comprehensive suite of option offers aimed at raising incremental capital, subject to shareholder approval at a December 23 meeting. The prospectus outlines potential dilution and financial impacts as the company seeks to strengthen its balance sheet.

Cyclopharm Limited has secured regulatory approval for its Technegas lung imaging technology in Colombia, marking its presence in 67 countries worldwide. This milestone aligns strategically with the upcoming global nuclear medicine congress in Cartagena.

Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.

Pure One Corporation Limited is set to exit its 40% stake in Turquoise Group for AUD 5 million, securing a substantial profit and refocusing on its core clean energy ventures.

IVE Group has agreed to acquire Australian creative agency Daily Press for up to $35 million, bolstering its digital, social, and performance marketing capabilities as part of its ‘Now to 2030’ growth strategy.